UPDATE | May 2, 2025

What do you see as the next big modality in biologics, and what factors are driving innovation in this space?

  • MAIL

What do you see as the next big modality in biologics, and what factors are driving innovation in this space?


Antibody-drug conjugates (ADCs) have demonstrated great potential, particularly in oncology, with the ability to improve targeted treatment outcomes. 


In a recent Pharma’s Almanac article, Samsung Biologics joined industry peers to share insights on the latest ADC advances ㅡ highlighting ongoing efforts to expand our offerings and deliver tailored services to clients through end-to-end capabilities.


Read More

What do you see as the next big modality in biologics, and what factors are driving innovation in this space?


Antibody-drug conjugates (ADCs) have demonstrated great potential, particularly in oncology, with the ability to improve targeted treatment outcomes. 


In a recent Pharma’s Almanac article, Samsung Biologics joined industry peers to share insights on the latest ADC advances ㅡ highlighting ongoing efforts to expand our offerings and deliver tailored services to clients through end-to-end capabilities.


Read More

  • CDO
  • CGMP
  • ADC
  • Bio Campus
  • IR
  • CMO

Share article

  • MAIL

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required